<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="34586">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02656329</url>
  </required_header>
  <id_info>
    <org_study_id>GE-122-020</org_study_id>
    <secondary_id>2015-001464-19</secondary_id>
    <nct_id>NCT02656329</nct_id>
  </id_info>
  <brief_title>International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical Device</brief_title>
  <acronym>ADMIRE-ICD</acronym>
  <official_title>AdreView™ Myocardial Imaging for Risk Evaluation - A Multicentre Trial to Guide ICD Implantation in NYHA Class II &amp; III Heart Failure Patients With 30%≤LVEF≤35%</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TFS Trial Form Support</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ICON plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GE Healthcare</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an event-driven Phase IIIb, multicentre, randomised, clinical study to demonstrate
      the efficacy of AdreView™ imaging for appropriately guiding the decision of implantable
      cardioverter defibrillator (ICD) implantation, in New York Health Association (NYHA) class
      II and III heart failure patients with 30%≤left ventricular ejection fraction (LVEF)≤35%%,
      and in particular, for identifying patients who are at low risk for sudden cardiac death and
      who would not benefit, or may suffer harm, from implantation of an ICD device.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Mean observational time of 2.75 to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare rate of hospitalisation and death related to major complications of ICD implantation and composite of rate of complications of long-term device therapy.</measure>
    <time_frame>Mean observational time of 2.75 to 3 years</time_frame>
    <description>A composite of the rate of hospitalization and death related to major complications of device implantation and a composite of the rate of complications of long-term device therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death (dosed of sudden cardiac death. death due to cardiac arrhythmias, death due to heart failure, and death due to other cardiovascular causes.</measure>
    <time_frame>Mean observational time of 2.75 to 3 years</time_frame>
    <description>Cardiac death (composed of sudden cardiac death, death due to cardiac arrhythmia, death due to heart failure, and death due to other cardiovascular causes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of all-cause hospitalization for cardiovascular cause.</measure>
    <time_frame>Mean observational time of 2.75 to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of the occurrence of resuscitated life-threatening ventricular tachycardia, unstable ventricular tach-arrhythmias, sudden cardiac death and resuscitated cardiac arrest.</measure>
    <time_frame>Mean observational time of 2.75 to 3 years</time_frame>
    <description>A composite of the occurrence of resuscitated life-threatening ventricular tachycardia, unstable ventricular tach-arrhythmias, sudden cardiac death and resuscitated cardiac arrest.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2216</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Arm 1- Iobenguane I-123 Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Iobenguane I-123 Injection. AdreView-guided ICD. Patients will receive a thyroid blocking agent before the Iobenguane I-123 Injection, AdreView, scan unless medically not indicated, according to local practice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 - Implantable Cardioverter Defibrillator</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iobenguane I -123 Injection</intervention_name>
    <description>Iobenguane I-123 Injection, AdreView. All patients will be scheduled for an Iobenguane I-123 Injection, AdreView scan.</description>
    <arm_group_label>Arm 1- Iobenguane I-123 Injection</arm_group_label>
    <other_name>AdreView</other_name>
    <other_name>Iobenguane I-123 Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantable Cardioverter Defibrillator</intervention_name>
    <description>In the Iobenguane I-123 Injection group, patient with H/M ratio less or equal to 1.6 will undergo ICD device implantation, while those with H/M ratio greater than or equal to 1.6 will not. All patients allocated to the SoC (control) group will undergo ICD implantation.</description>
    <arm_group_label>Arm 2 - Implantable Cardioverter Defibrillator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thyroid blocking</intervention_name>
    <description>Patients will receive a thyroid blocking agent before the Iobenguane I-123 Injection, AdreView, scan unless medically not indicated, according to local practice.</description>
    <arm_group_label>Arm 1- Iobenguane I-123 Injection</arm_group_label>
    <other_name>Potassium Iodide</other_name>
    <other_name>Potassium Perchlorate</other_name>
    <other_name>Lugol's Solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥18 years of age at the time dated informed consent is obtained.

          -  Female patients must be pre-menarchal, surgically sterile (had a documented bilateral
             oophorectomy and/or documented hysterectomy), postmenopausal (cessation of menses for
             more than 1 year), non-lactating, or, if of childbearing potential, a serum or urine
             pregnancy test with the results known prior to AdreView (Iobenguane I-123 Injection)
             administration) is negative.

          -  Patients willing and able to comply with all study procedures and a signed and dated
             informed consent is obtained before any study-procedure is carried out.

          -  Heart failure NYHA classes II or III for symptoms, patients with ischemic or
             non-ischemic heart disease, eligible for ICD implantation as per each site's standard
             of practice.

          -  Heart failure NYHA classes II or III for symptoms, patients with ischemic or
             non-ischemic heart disease, eligible for ICD implantation as per each site's standard
             of practice.

          -  Non-ischemic dilated cardiomyopathy or ischemic heart disease of at least 3 months
             duration.

          -  30%≤LVEF≤35%, performed within 3 months before or at time of enrolment, as measured
             by radionuclide ventriculography, or electrocardiogram [ECG]-gated SPECT myocardial
             perfusion imaging [MPI], or magnetic resonance imaging [MR], computed tomography
             [CT], or 3D or 2D echocardiography [Simpson's or multidisc method only, M-mode
             echocardiography is not accepted].

        In case LVEF measurement is performed within 3 months before enrolment, measurement should
        be performed at least 40 days after a hospitalisation for HF or acute coronary syndrome
        (including myocardial infarction), and to be valid, method of measurement should be in
        accordance with the protocol and the imaging exam should be made available to the Sponsor
        in digital format. In case several valid LVEF measurements are available, the closest to
        enrolment will be used for inclusion determination.

          -  Clinically stable heart failure in the medical judgment of the investigator (i.e. no
             significant changes in medication, no worsening of symptoms, no unscheduled visits to
             the doctor's office) for the past 30 days and no hospitalisation for heart failure or
             acute coronary syndrome (including myocardial infarction) in the past 40 days.

          -  Reasonable expectation of meaningful survival for at least 1 year.

        Exclusion Criteria:

          -  Patients with existing ICD or patient having an indication of ICD implantation for
             secondary prevention of sudden cardiac death.

          -  Hospitalisation for HF or for acute coronary syndrome in the previous 40 days.

          -  Patients where a cardiac resynchronisation therapy (CRT) is planned or indicated.

          -  Other indication for placement of device (sustained ventricular tachycardia,
             resuscitated sudden death, need for atrioventricular pacing).

          -  NYHA class I or class IV symptoms at the time of study entry.

          -  Patient with chronic renal insufficiency defined as serum creatinine ≥ 3 mg/dl (or
             265.2 µmol/L).

          -  American College of College-American Heart Association (ACC-AHA) class III or class
             IV (unstable) angina.

          -  Known or suspected hypersensitivity/allergy to Iobenguane or to any of the excipients
             an Adreview (Iobenguane I-131 injection).

          -  Patient who is pregnant or plans to become pregnant within 2 weeks after AdreView
             (Iobenguane I-123 Injection) administration.

          -  Patient who has used any medication in the 2 weeks before AdreView (Iobenguane I-123
             Injection) that could interfere with the test: e.g. but not limited to amitriptyline
             or derivatives, imipramine or derivatives, other antidepressants or drugs known or
             suspected to inhibit the norepinephrine transporter, antihypertensives that deplete
             norepinephrine stores or inhibit reuptake, sympathomimetic amines or cocaine.

          -  Patients that have a medical condition that could interfere with the AdreView test
             (e.g. but not limited to left ventricular assist device (LVAD), or prior heart
             transplant).

          -  Patients who participated in a clinical study involving a drug or device within 30
             days prior to study entry and patients participating in any other clinical study.

          -  Patients having serious non-cardiac medical condition associated with significant
             elevation of plasma catecholamines, including pheochromocytoma.

          -  Patients with a clinical diagnosis of (or being treated for) Parkinson's disease or
             Multiple System Atrophy.

          -  The patient has participated in a research study using ionizing radiation in the
             previous 12 months.

          -  The patient has participated in a research study using ionizing radiation in the
             previous 12 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thomas Koperniak, PhD</last_name>
    <phone>774-843-3908</phone>
    <email>Thomas.Koperniak@ge.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jay Chahal</last_name>
    <phone>44-1494-543915</phone>
    <email>Jay.Chahal@ge.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Comprehensive Cardiovascular Medical Group</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cardiology Physicians PA/Red Clay Research, LLC</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bethesda Health</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UF Health Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cardiology Consultants</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cardiovascular Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MedStar Shah Medical Group</name>
      <address>
        <city>Charlotte Hall</city>
        <state>Maryland</state>
        <zip>20622</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Cardiology Group</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Institute of Cardiology, PA</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75071</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Victoria Heart and Vascular Center</name>
      <address>
        <city>Victoria</city>
        <state>Texas</state>
        <zip>77901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 1N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Alexandra Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5H3V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Brno Bohunice</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice u sv. Anny v Brne</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>FN Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krajska nemocnice Liberec</name>
      <address>
        <city>Liberec</city>
        <zip>460 63</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Plzen</name>
      <address>
        <city>Plzen-Lochotin</city>
        <zip>304 60</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice v Kralovske Vinohrady</name>
      <address>
        <city>Praha 10</city>
        <zip>100 34</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice v Motole</name>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Masarykova nemocnice v Usti nad Labem</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>40001</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHR Metz-Thionville - Site de Mercy</name>
      <address>
        <city>Ars Laquenexy</city>
        <zip>57530</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH Antoine Beclere</name>
      <address>
        <city>Clamart</city>
        <zip>92140</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Varosmajori Sziv es Ergyogyaszati Klinika</name>
      <address>
        <city>Budapest</city>
        <zip>1112</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Budai Irgalmasrendi Korhaz</name>
      <address>
        <city>Budapest</city>
        <zip>H-1023</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem, Kardiologia Intezet and ScanoMed Nuclear Medicine Institute</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Federico II Dipartimento ad Attivita Integrata di Cardiologia,Cardiochirurgia ed Emergenze Cardiovascolari</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Scienze Cardiovascolari, Respiratorie Neufrologiche e Geriatriche - Universita di Roma &quot;La Sapienza&quot;</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwen Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1091 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Amphia Zickenhuis</name>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny w Bialymstoku</name>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Centralny Szpital Kliniczny</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar (Murcia)</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma de Mallorca (Illes Balears)</city>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Juan de Alicante</name>
      <address>
        <city>San Juan Alicante</city>
        <zip>03550</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela (A Coruña)</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 22, 2017</lastchanged_date>
  <firstreceived_date>January 7, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure (HF)</keyword>
  <keyword>Single photon emission computer tomography scan (SPECT)</keyword>
  <keyword>Implantable cardioverter defibrillator (ICD)</keyword>
  <keyword>Left Ventricular ejection fraction (LVEF)</keyword>
  <keyword>New York Health Association (NYHA)</keyword>
  <keyword>Metaiodobenzylguanidine (mIBG)</keyword>
  <keyword>123I-iobenguane</keyword>
  <keyword>Heart-to-mediastinal ratio (H/M)</keyword>
  <keyword>ADMIRE-ICD (AdreView Myocardial Imaging for Risk Evaluation - Implantable Cardioverter Defibrillator</keyword>
  <keyword>All-cause mortality</keyword>
  <keyword>Cardiac mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lugol's solution</mesh_term>
    <mesh_term>3-Iodobenzylguanidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
